As of June 30, 2025, cash and cash equivalents totaled $22.3 million. The Company believes that it has sufficient resources to fund operations into the second half of 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics announces publication of OLC trial data
- Unicycive Regains Nasdaq Compliance After Stock Split
- Unicycive Therapeutics regains compliance with Nasdaq bid price requirement
- Unicycive Therapeutics approval delay ‘not a surprise,’ says Noble Capital
- Unicycive Receives FDA CRL for New Drug Application